Naitee Ting, Ph.D., is a director of biostatistics in the Department of Biostatistics and Data Sciences at Boehringer-Ingelheim Pharmaceuticals Inc. (BI). Dr. Ting joined Boehringer- Ingelheim in September 2009. Prior to his tenure at BI, Dr. Ting worked for twenty-two years (1987-2009) at Pfizer Inc.
In 1987, Dr. Ting earned his Ph.D. in statistics under the supervision of Dr. Franklin A. Graybill from Colorado State University. Before his Ph.D. work, Naitee matriculated at Mississippi State University (M.S. in statistics, 1979) and the College of Chinese Culture (B.S. in forestry, 1976). With research interests in dose response and clinical study designs, as well as in bioequivalence and confidence intervals for variance components, Dr. Ting has published about 60 articles appearing in book chapters and peer-reviewed journals. He has co-authored two books, Fundamental Concepts for New Clinical Trialists (Chapman Hall/CRC, 2016) and Phase Ⅱ Clinical Development of New Drugs (Springer, 2017), and co-edited three books, Dose Finding in Drug Development (Springer, 2006), Applied Statistics in Biomedicine and Clinical Trials Design: Selected Papers from 2013 ICSA/ISBS Joint Statistical Meetings (Springer, 2015), and Design and Analysis of Subgroups with Biopharmaceutical Applications (Springer, 2020). He has delivered numerous invited lectures to universities and in conferences, workshops, and colloquia.
Dr. Ting is an elected fellow of the American Statistical Association (ASA). He received Certificate of Appreciation from the International Chinese Statistical Association (ICSA) in 1999 in recognition and with sincere appreciation for his contributions in organizing the 1998 Applied Statistics Symposium. He earned the Distinguished Service Award from ICSA in 2001 in recognition and with sincere appreciation for his dedicated effort, unselfish support, and distinguished service. He was the first Honored Statistician of Connecticut Chapter of ASA in 2003 for his continuing service to the Chapter, the national ASA, and the statistics profession.
Dr. Ting served as president of Connecticut Chapter of ASA in 1991-1992, executive director of ICSA in 1998-2000, a member of the Board of Directors of ICSA in 2002-2004, chair of the Biometrics Section of ICSA in 2003, chair of the Program Committee of ICSA in 2004-2007, and council of sections representative of Biopharmaceutical Section of ASA in 2005-2007. He also served as a member of the Committee on ASA Archives and Historical Materials and the Executive Committee and National Committee on Videos of Distinguished Statisticians – a Joint Program of Pfizer, the University of Connecticut and the ASA in 2004-2009, chair of the Archive Committee of ICSA in 2009-2012, chair of the Nomination Committee of ICSA in 2013, and a member of the Deming Conference Program Committee in 2010 - present. Currently, he serves as vice president for Strategies & Development of the New England Statistical Society.
Dr. Ting served as associate editor for Journal of Biopharmaceutical Statistics in 2006 – 2010 and Drug Information Journal in 2003-2012. He also served as a guest co-editor for a special issue of Journal of Biopharmaceutical Statistics (Volume 16, Number 5, 2006) on “Design and Analysis of Dose-Response Clinical Trials,”, a guest co-editor for a special issue of Statistics in Biosciences (volume 12, number 2, 2020) on “Statistical Methods for Cancer Immunotherapy”, and a guest co-editor for a special issue of Statistics in Biosciences on “Leveraging External Data to Improve Trial Efficiency” in 2021-2022.
Dr. Ting’s 2006 book Dose Finding in Drug Development is highly regarded by his peers, and is considered a leading reference in the environs of dose response for clinical trials. Serving as an adjunct professor who teaches semester-long courses in clinical trials and regression analysis at Columbia University, University of Connecticut and Colorado State University, Dr. Ting is a passionate educator who has eagerly helped countless students, junior researchers, and senior researchers in the statistical community. Additionally, he has mentored many professionals in the field of drug development. Dr. Ting’s lecture series “Pharmaceutical Statistics,” publicized on Youtube by ASA in 2021, is considered as one of the leading educational tools for scientists and professionals engaged in new drug development.